{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:37:00Z","timestamp":1772789820331,"version":"3.50.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/13696998.2024.2331893","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T11:39:55Z","timestamp":1713526795000},"page":"531-542","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6929-8691","authenticated-orcid":false,"given":"G\u00fcnter","family":"Niegisch","sequence":"first","affiliation":[{"name":"Department of Urology, University Hospital and Medical Faculty of the Heinrich-Heine-University","place":["D\u00fcsseldorf, Germany"]},{"name":"Center for Integrated Oncology, Aachen Bonn Cologne D\u00fcsseldorf","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-8654","authenticated-orcid":false,"given":"Marc-Oliver","family":"Grimm","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Jena","place":["Jena, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-1628","authenticated-orcid":false,"given":"Fraence","family":"Hardtstock","sequence":"additional","affiliation":[{"name":"Cytel","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5816-0611","authenticated-orcid":false,"given":"Julia","family":"Krieger","sequence":"additional","affiliation":[{"name":"Cytel","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-511X","authenticated-orcid":false,"given":"Alexandra","family":"Starry","sequence":"additional","affiliation":[{"name":"Cytel","place":["Berlin, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[{"name":"Merck Healthcare Germany GmbH, Weiterstadt, Germany, an affiliate of Merck KGaA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1630-8080","authenticated-orcid":false,"given":"Barthold","family":"Deiters","sequence":"additional","affiliation":[{"name":"GWQ ServicePlus AG","place":["D\u00fcsseldorf, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Maywald","sequence":"additional","affiliation":[{"name":"Drug Department, AOK PLUS","place":["Dresden, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8932-6426","authenticated-orcid":false,"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[{"name":"IPAM e.V.","place":["Wismar, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA","place":["Darmstadt, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102142"},{"key":"e_1_3_2_3_1","unstructured":"World Health Organization. Bladder fact sheet [cited 2022 Nov 08]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/30-bladder-fact-sheet.pdf"},{"key":"e_1_3_2_4_1","unstructured":"Witjes JA Bruins HM Carri\u00f3n A et\u00a0al. EAU guidelines on muscle-invasive and metastatic bladder cancer; 2022 [cited 2022 Nov 07]. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.033"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12601"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.07.025"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1591424"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211047352"},{"key":"#cr-split#-e_1_3_2_10_1.1","unstructured":"Robert Koch-Institut. Cancer in Germany 2017\/2018"},{"key":"#cr-split#-e_1_3_2_10_1.2","unstructured":"2021 [cited 2022 Nov 05]. Available from: https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_inhalt.html"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.23162"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0540-8"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.08.007"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"e_1_3_2_16_1","unstructured":"Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie\/Anlage XII: Atezolizumab (Urothelkarzinom). Berlin: G-BA; 2018 [cited 2023 Jun 14]. Available from: https:\/\/www.g-ba.de\/downloads\/39-261-3256\/2018-03-16_AM-RL-XII_Atezolizumab_D-314_BAnz.pdf"},{"key":"e_1_3_2_17_1","unstructured":"Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie\/Anlage XII: Pembrolizumab (neues Anwendungsgebiet: Urothelkarzinom). Berlin: G-BA; 2018 [cited 2023 Jun 14]. Available from: https:\/\/www.g-ba.de\/downloads\/39-261-3257\/2018-03-16_AM-RL-XII_Pembrolizumab_D-311_BAnz.pdf"},{"key":"e_1_3_2_18_1","unstructured":"Gemeinsamen Bundesausschusses (G-BA). Arzneimittel-Richtlinie\/Anlage XII: Nivolumab (neues Anwendungsgebiet: Urothelkarzinom). Berlin: G-BA; 2017 [cited 2023 Jun 14]. Available from: https:\/\/www.g-ba.de\/beschluesse\/3170\/"},{"key":"e_1_3_2_19_1","unstructured":"Gemeinsamen Bundesausschusses (G-BA). Anlage XII \u2013 Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V: Avelumab. Berlin: G-BA; 2021 [cited 2023 Jun 14]. Available from: https:\/\/www.g-ba.de\/downloads\/39-261-4981\/2021-08-19_AM-RL-XII_Avelumab_D-646_BAnz.pdf"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.464"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00574-0"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.024"},{"key":"e_1_3_2_24_1","unstructured":"Destatis (Statistisches Bundesamt). Bev\u00f6lkerungsstand: Amtliche Einwohnerzahl Deutschlands; 2022. Wiesbaden: Destatis; 2023 [cited 2023 Jun 14]. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/_inhalt.html"},{"key":"e_1_3_2_25_1","volume-title":"Evidence generation in health services research - illustrative examples and conceptual thoughts on claims data-based applications: Helmholtz Zentrum M\u00fcnchen \u2013 Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH)","author":"Schwarzkopf L.","year":"2018","unstructured":"Schwarzkopf L. Evidence generation in health services research - illustrative examples and conceptual thoughts on claims data-based applications: Helmholtz Zentrum M\u00fcnchen \u2013 Deutsches Forschungszentrum f\u00fcr Gesundheit und Umwelt (GmbH). Munich (Germany): Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 2018."},{"key":"e_1_3_2_26_1","unstructured":"De Wit M Bauernhofer T Bokemeyer C et\u00a0al. Blasenkarzinom (Urothelkarzinom). Berlin (Germany): DGHO (Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie); 2019."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"e_1_3_2_29_1","unstructured":"Destatis. (Statistisches Bundesamt.). Per capita costs of illness for men and women continue to converge 2022 [cited 2024 Mar 20]. Available from: https:\/\/www.destatis.de\/EN\/Press\/2022\/07\/PE22_316_236.html"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.261"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.001"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0395-z"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0682-5"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"e_1_3_2_35_1","unstructured":"Bundesministerium f\u00fcr Gesundheit. \u00a7 39 SGB V Krankenhausbehandlung; 2023 [cited 2023 Jun 14]. Available from: https:\/\/www.sozialgesetzbuch-sgb.de\/sgbv\/39.html"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2014.08.003"},{"key":"e_1_3_2_37_1","volume-title":"TNM classification","author":"Rosen RD","year":"2024","unstructured":"Rosen RD, Sapra A. TNM classification. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.zefq.2023.01.001"},{"key":"e_1_3_2_39_1","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V; 2017 [cited 2022 Nov 04]. Available from: https:\/\/www.iqwig.de\/download\/a21-34_pembrolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_2_40_1","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom Erstlinientherapie) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V; 2017 [cited 2022 Nov 04]. Available from: https:\/\/www.iqwig.de\/download\/a17-51_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf"},{"key":"e_1_3_2_41_1","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom) \u2013 Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V; 2017 [cited 2022 Nov 05]. Available from: https:\/\/www.iqwig.de\/download\/a17-29_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf?rev=117386"},{"key":"e_1_3_2_42_1","unstructured":"Bundesministerium f\u00fcr Gesundheit. Versicherte in der gesetzlichen Krankenversicherung; 2022 [cited 2023 Apr 11]. Available from: https:\/\/www.bundesgesundheitsministerium.de\/gesetzlich-versicherte.html#:\u223c:text=Kinder%2C%20Ehegattinnen%20und%20Ehegatten%20sowie eine%20bestimmte%20Einkommensgrenze%20nicht%20regelm%C3%A4%C3%9Fig"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2024.2331893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:45:56Z","timestamp":1772779556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2024.2331893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/13696998.2024.2331893"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2024.2331893","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}